Interchangeability 101 – Biosimilars & Interchangeable Biologics

Friday May 3, 2019

Biosimilars are safe, effective medicines for patients that treat some of the most difficult-to-treat conditions such as psoriasis, rheumatoid arthritis and cancer. These important treatment options offer increased patient access and can potentially save the health care system billions of dollars. Interchangeable biologics are biosimilars that are approved by the FDA to be substituted by a third party for the reference biologic. Patients can rely on the safety of these products just as they would the reference medicine. Watch this important video to learn more about biosimilars, including:

  • Biosimilars are clinically equivalent to their reference medicines. They are just as safe and just as effective as the biologic they are based on.
  • Biosimilars are often available at a much lower cost than their biologic counterpart. Like all biologic medicines, a doctor prescribes a biosimilar to his or her patient.
  • A doctor may prescribe a patient an interchangeable biologic.
  • An interchangeable biologic is not superior in quality to a biosimilar product as both have to meet the very same high standards.

Watch this new video from the Biosimilars Council to learn more about biosimilars, biologics and interchangeability.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.